Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Short Interest Up 327.4% in May

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) saw a large increase in short interest in May. As of May 29th, there was short interest totaling 50,407 shares, an increase of 327.4% from the May 14th total of 11,793 shares. Based on an average daily volume of 359,949 shares, the short-interest ratio is presently 0.1 days. Currently, 0.0% of the company’s stock are short sold.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Zacks Research raised shares of Chugai Pharmaceutical to a “hold” rating in a research note on Friday, May 29th. Smbc Nikko Sec. upgraded shares of Chugai Pharmaceutical to a “strong-buy” rating in a research note on Wednesday, February 25th. Two equities research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, Chugai Pharmaceutical currently has a consensus rating of “Buy”.

Chugai Pharmaceutical Stock Down 0.4%

Shares of CHGCY stock traded down $0.09 during trading on Thursday, reaching $23.19. 420,444 shares of the company’s stock were exchanged, compared to its average volume of 235,537. Chugai Pharmaceutical has a twelve month low of $19.50 and a twelve month high of $34.84. The firm’s fifty day moving average price is $25.81 and its 200-day moving average price is $27.23. The stock has a market capitalization of $76.32 billion, a PE ratio of 25.76 and a beta of 0.58.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last released its quarterly earnings data on Friday, April 24th. The company reported $0.22 EPS for the quarter. Chugai Pharmaceutical had a net margin of 34.98% and a return on equity of 22.90%. The firm had revenue of $2.05 billion during the quarter. As a group, analysts anticipate that Chugai Pharmaceutical will post 0.98 EPS for the current fiscal year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.